VICTORIA, May 7, 2015 /CNW/ - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"), a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP") under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR"), is pleased to announce that its wholly owned subsidiary Thunderbird Biomedical Inc. has received a notice from Health Canada dated May 6, 2015 confirming the renewal of its production license, and including the expansion of its license to include full authorization to commence medical marijuana sales.

"We are very excited to have secured our sales license and look forward to begin servicing medical marijuana patients and executing on our patient acquisition and commercial roll out strategy.  We can now begin providing Canadian patients with high quality medicinal marijuana," said Dr. Bin Huang, President and CEO of T-Bird Pharma Inc.  "In addition to our ongoing commitment to scientific and clinical research, we have spent considerable time developing quality assurance and customer service...